Navigation Links
Foamix Receives US Patent on Novel Foam Technology
Date:8/24/2009

NESS ZIONA, Israel, August 24 /PRNewswire/ -- Foamix Ltd., a leading developer of topical foams for dermatology and gynecology, announced today that it has been awarded US Patent #7575739 pertaining to its foam technology. The patent covers unique foam compositions, suitable for the treatment of heat and chemical burns, wounds, bacterial, fungal and viral infections.

Dr. Dov Tamarkin, the Company's CEO stated, "The novelty of our foam technology platform is that it enables facile delivery of active agents to the inflicted site. Our foams are breakable - they are easily applied to the sensitive area of wounds and burns and they are absorbed readily into the treated area."

Foamix expends significant resources on protecting its intellectual property. To date, Foamix has five issued U.S. patents covering its OilGel(TM) and topical foam technology platforms. An additional 70 U.S. patent applications, protecting its proprietary foam platforms are under prosecution, covering compositions, applications, methods of use and delivery devices. The Company employs leading U.S. patent counsel (Wilmer Hale, Boston) as well as an in-house intellectual property team.

About Foamix

Headquartered in Ness Ziona, Israel, Foamix Ltd. is a leading developer of topical foams for dermatology and gynecology. Foamix's state-of-the-art foams provide controlled delivery of a variety of active ingredients. Foamix is currently collaborating with 10 pharmaceutical and cosmetic companies on 12 projects in the development of proprietary dermatological and gynecologic foam drugs. Additionally, the Company has an extensive in-house pipeline of dermatological and gynecological drugs in foam presentation.

Foamix holds 5 US patents and has 70 patents pending in the United States.

For additional information please visit http://www.foamix.co.il

Press inquiries: Sigal Maymon, Foamix Ltd, +972-8-9316233 or info@foamix.co.il


'/>"/>
SOURCE Foamix Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Ferndale and Foamix Execute License Agreement for Development of Non-Steroidal Foam for Atopic Dermatitis
2. Foamix Signs Term Sheet to Acquire License to Organo-Boron Antifungal Molecules - Will Target the $11 Billion Dollars Fungal Infection Market
3. Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis
4. SyntheMed Receives Russian Regulatory Approval for REPEL-CV(TM)
5. Vasogen Receives NASDAQ Notification Related to Minimum Bid Price
6. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
7. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets
8. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material
9. China-Biotics, Inc. Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate
10. YM BIOSCIENCES USA RECEIVES CLEARANCE FROM US TREASURY DEPARTMENT TO EXTEND CLINICAL PROGRAM FOR NIMOTUZUMAB
11. REPEL-CV(TM) Adhesion Barrier Receives Endorsement of Kids With Heart
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Feb. 23, 2017 China Biologic Products, Inc. (NASDAQ: ... plasma-based biopharmaceutical company in China, today announced its financial results ... Fourth Quarter 2016 Financial Highlights ... by 21.7% in RMB terms, or increased by 13.6% in ... same quarter of 2015. Gross profit increased ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... Services portfolio to include an array of biochemical analyses critical for Lead ... to drive their hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism ...
(Date:2/23/2017)... 23, 2017  Imanis Life Sciences announced today ... oncolytic vaccinia viruses for virotherapy research. These viruses ... Genelux,s proprietary, vaccinia virus-based technology platform for research ... into a partnership with Genelux to offer researchers, ... for use in research," said Dr. Kah ...
(Date:2/23/2017)... Winston-Salem, NC (PRWEB) , ... February 23, 2017 , ... ... pleased to announce a new partnership with Compass Research . GGI's mission is ... gifting a vaccine to a child in need in honor of each clinical trial ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 2, 2017  EyeLock LLC, a market leader ... white paper " What You Should Know About Biometrics ... ensuring user authenticity is a growing concern. In traditional ... users. However, traditional authentication schemes such as username/password suffer ... Biometric authentication offers an elegant solution to the problem ...
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market ... for Biometrics and Digital Identity".  Acuity characterizes 2017 ... identity when increased adoption reflects a new understanding ... "Biometrics and digital identity are often ... Maxine Most , Principal of Acuity Market ...
Breaking Biology News(10 mins):